Segall Bryant & Hamill LLC Invests $649,000 in Omnicell, Inc. (NASDAQ:OMCL)

Segall Bryant & Hamill LLC acquired a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 14,585 shares of the company’s stock, valued at approximately $649,000.

A number of other hedge funds have also recently bought and sold shares of the company. Smartleaf Asset Management LLC lifted its stake in shares of Omnicell by 51.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock worth $35,000 after purchasing an additional 273 shares during the period. Van ECK Associates Corp boosted its stake in Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after buying an additional 315 shares during the last quarter. First Horizon Advisors Inc. boosted its stake in Omnicell by 36.3% in the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock worth $59,000 after buying an additional 355 shares during the last quarter. Redmond Asset Management LLC increased its stake in shares of Omnicell by 0.3% during the 4th quarter. Redmond Asset Management LLC now owns 121,209 shares of the company’s stock valued at $5,396,000 after acquiring an additional 371 shares during the last quarter. Finally, Hillsdale Investment Management Inc. lifted its holdings in shares of Omnicell by 0.5% during the 4th quarter. Hillsdale Investment Management Inc. now owns 92,897 shares of the company’s stock worth $4,136,000 after acquiring an additional 420 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Stock Performance

OMCL stock opened at $35.01 on Friday. The firm has a market cap of $1.64 billion, a P/E ratio of 129.67, a P/E/G ratio of 7.53 and a beta of 0.85. The stock’s 50 day simple moving average is $39.01 and its 200 day simple moving average is $42.58. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 12-month low of $25.12 and a 12-month high of $55.75.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, equities research analysts predict that Omnicell, Inc. will post 1.09 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently commented on OMCL. Benchmark reaffirmed a “buy” rating and set a $62.00 price target on shares of Omnicell in a research report on Tuesday, February 4th. Bank of America dropped their price objective on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research report on Monday, January 6th. Wells Fargo & Company reduced their price objective on Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. JPMorgan Chase & Co. dropped their target price on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a report on Thursday, March 20th. Finally, StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Monday, March 24th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $51.00.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.